Compare Sanofi SA (SNY) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Sanofi SA trades at $42.96 (market cap $103.41B), while iShares 20 Plus Year Treasury Bond ETF trades at $81.42. The key difference: Sanofi SA pays a 5.65% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and Sanofi SA is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| SNY | TLT | |
|---|---|---|
Market Cap | $103.41B | — |
Sector | Health | — |
52-Week High | $52.34 | $92.06 |
52-Week Low | $41.33 | $81.35 |
Enterprise Value | $123.44B | — |
Dividend Yield | 5.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
TLT trades at $82.20, down slightly by 0.01% with a bearish technical signal from moving averages. The ETF faces headwinds from rising Treasury yields and potential large-scale selling by institutional investors like Norway's sovereign wealth fund. Recent Treasury buyback announcements of up to $6 billion in long-dated debt provide some support, but the overall trend remains challenging amid inflation concerns and rising oil prices.
The outlook for TLT remains cautious as rising interest rates and inflation pressures continue to weigh on long-duration bonds. While current RSI levels suggest potential oversold conditions, the fundamental environment of higher yields and potential institutional selling creates significant downside risk. Investors should monitor Treasury policy actions and global bond market developments closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
